摘要
目的探讨羟苯磺酸钙联合丹红注射液治疗非增殖型糖尿病视网膜病变(DR)的临床疗效及安全性。方法收集2012年1月至2014年1月吉化集团公司总医院眼科收治的80例(124只眼)非增殖型DR患者的临床资料。按照随机数字表法将患者分为观察组40例(64只眼)和对照组40例(60只眼)。两组患者均给予降血糖治疗,对照组加用丹红注射液进行治疗,观察组加用丹红注射液及羟苯磺酸钙进行治疗,治疗后3个月比较两组患者的临床疗效。两组患者的临床效果按照显效、有效和无效分为3个等级,以例数和百分比的形式表示,并采用Kruskal-Wallis H秩和检验的方法进行组间比较。治疗前后两组患者的视力以均数±标准差(x珋±s)的形式表示,并采用配对t检验的方法进行组内比较,采用独立样本t检验的方法进行组间比较。治疗后两组患者并发症的发生情况采用χ2检验的方法进行比较。结果经过3个月的治疗后,观察组显效者26例(42只眼),占65.63%;有效者12例(20只眼),占31.25%;无效者2例(2只眼),占3.12%。对照组显效者20例(31只眼),占51.67%;有效者12例(16只眼),占26.67%;无效者8例(13只眼),占21.67%,观察组患者的临床治疗效果明显优于对照组,差异有统计学意义(Hc=10.05,P<0.05)。治疗前观察组患者的视力为(0.31±0.08),治疗后观察组患者的视力为(0.56±0.17),治疗前后观察组患者的视力比较,差异有统计学意义(t=10.64,P<0.05)。治疗前对照组患者的视力为(0.34±0.10),治疗后对照组患者的视力为(0.45±0.13),治疗前后对照组患者的视力比较,差异有统计学意义(t=3.98,P<0.05)。治疗前观察组和对照组患者的视力比较,差异无统计学意义(t=1.83,P>0.05)。治疗后观察组和对照组患者的视力比较,差异有统计学意义(t=8.90,P<0.05)。观察组发生并发症的患者共4例(10.00%),其中食欲下降者2例(5.00%),面部发红者1例(2.50%),恶心、呕吐者1例(2.50%),对症处理后症状消失,均未影响正常治疗。对照组有2例(5.00%)患者出现面部发红,调整输液速度后症状消失,治疗后两组患者不良反应的发生情况比较,差异有统计学意义(χ2=0.02,P>0.05)。结论羟苯磺酸钙联合丹红注射液治疗非增殖型DR能有效提高患者的视力,改善患者眼底的功能,延缓病程,值得临床推广应用。
Objective To evaluate the clinical efficacy and safety of calcium dobesilate combined with Danhong in the treatment of non-proliferative diabetic retinopathy （ NPDR） .Methods Patients with NPDR who met the inclusion criteria were randomized to receive Danhong treatment （40 patients,64 eyes） and Danhong plus calcium dobesilate （40 patients,60 eyes）,respectively,in addition to glucose-lowering therapy.At 3 months after treatment,patient outcomes and treatment-associated complications were assessed. Results The combined treatment with Danhong and calcium dobesilate was markedly effective in 42 （65.63%） eyes,moderately effective in 20（31.25%） eyes and in effective in 2（3.12%） eyes.In contrast, the mono-treatment with Danhong was markedly effective in 31 （51.67%） eyes,moderately effective in 16 （26.67%） eyes, and ineffective in 13 （ 21.67%） eyes.The overall treatment efficacy was significantly higher in the combined treatment group than that in control group （Hc=10.05,P 〈0.05）.Before the treatmen,the vision of observation group is （0.31±0.08） mmol/L,which is belower than after treatment （0.56±0.17）,the difference have the statistically significan t （t=10.64,P〈0.05）.Before the treatmen, the vision of control group is （0.34±0.10）,which is belower than after treatment （0.45±0.13）,the difference have the statistically significan t （t=3.398,P 〈00.5 ）.After treatment,the vision of observation group is higher than that control group,the difference also have the statistically significant （t=8.90,P 〈0.05）.There are four patients （10 .00%）have the complication in the observation group .Two of these patients （5.00%） were loss of appetite,one of these patients （2.50%） was facial redness and the other one （2.50%） is nausea and vomiting.After the expectant treatment, these complications were cured and did not affect the therapy.In the control group,there are two patient appeared with the complication of facial redness. After the adjusting the infusion speed, the complication were disappeared.This comparison of the patient′s adverse reaction between the observation group and control group has the statistically significant because of （χ2=00.2 ,P 〉0.05）.Conclusions It appears that calcium dobesilate combined with Danhong can more effectively improve fundus function and vision and delay the disease progression in NPDR patients than Danhong alone,thus offering a superior treatment option.
出处
《中华眼科医学杂志（电子版）》
2015年第2期18-21,共4页
Chinese Journal of Ophthalmologic Medicine(Electronic Edition)
关键词
非增殖型视网膜病变
糖尿病
羟苯磺酸钙
丹红
眼底病变
Non-propagative retinopathy
Diabetes
Calcium dobesilate capsule
Danhong injection
Fundus lesions
